Gustavo Alameda, MD
Neurology · Fort Lauderdale, FLNPI 1225233521
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,050 of the $4,221 with a category attached, or 95.9%. Amylyx Pharmaceuticals, Inc. accounts for 99.5% of it on its own, with 1 other manufacturer making up the rest.
Across 5 payments — averaging $844.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amylyx Pharmaceuticals, Inc.$4K
- Life Molecular Imaging Ltd$23
Across 22 payments — averaging $4225.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$54K
- PTC Therapeutics, Inc.$23K
- Biohaven Pharmaceutical Holding Company Ltd.$8K
- Amylyx Pharmaceuticals, Inc.$8K
- Novartis$188
What the payments were for
- Speaking & faculty fees$4,05096%
- Food & beverage$1714%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amylyx Pharmaceuticals, Inc. | 4 | $4,199 |
| Life Molecular Imaging Ltd | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RELYVRIO$4,050
How this compares
$4,221 in reported general payments places this provider in the 60th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 46 | $633,019 |
| Kesimpta PenOfatumumab | 15 | $144,797 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $22,106 |
| Aimovig AutoinjectorErenumab-Aooe | 31 | $22,013 |
| Dalfampridine ErDalfampridine | 26 | $10,777 |
| Emgality PenGalcanezumab-Gnlm | 11 | $7,381 |
| FingolimodFingolimod Hcl | 11 | $6,196 |
| Riluzole | 18 | $3,063 |
| Pregabalin | 52 | $1,133 |
| Pyridostigmine Bromide | 11 | $1,010 |
| Gabapentin | 35 | $793 |
| Baclofen | 37 | $745 |
| Memantine Hcl | 12 | $292 |
| Celecoxib | 14 | $221 |
| Prednisone | 20 | $185 |
Paid to pharmacies, not to this prescriber.
Other neurology in Fort Lauderdale
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
- Tuan VuTampa$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.